Perspective Therapeutics Q3 revenue up 27% to $2.19M; net loss widens to $10.4M

Perspective Therapeutics, Inc.

2024-Q3 EPS reported -$0.83 revenue$6,336,000

Revenue $2.19M (+27% YoY); sales revenue $1.9M (+11%); gross profit $738K vs $414K.
Net loss $10.4M ($0.04/sh) vs $4.1M ($0.03/sh); R&D expenses surged 708% to $5.7M.
Cash $18.0M at Sept 30, 2023 (from $43.9M at Dec 31, 2022); runway into late Q2 2024.
Dosed first patient in Phase 1/2a trial of [212Pb]VMT-α-NET for neuroendocrine tumors.
Completed recruitment for first cohort of Phase 1/2a VMT01 trial for melanoma; no serious AEs.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.85

Perspective Therapeutics, Inc. reported financial results for third quarter ended September 30, 2023.

Period: third quarter ended September 30, 2023
Result: reported results

Exact text from the filing

issued a press release announcing its financial results for the quarter ended September 30, 2023 and providing recent business highlights

View on SEC.gov

38 earnings releases filed in the last 30 days. Browse all earnings releases →

Perspective Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001437749-23-031996

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.